News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Comprehensive Cancer Network Collaborates with AVEO Pharmaceuticals, Inc. (AVEO) and Astellas Pharma Inc. (YPH.BE) on Innovative Cancer Research


2/17/2012 6:45:06 AM

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that it has entered into a collaboration with AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. (Tokyo: 4503) to develop oncology research protocols and trials examining tivozanib as a single agent and in combination with other drugs and biologics in the treatment of solid tumors. Tivozanib is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors. The VEGF pathway plays a distinct role in angiogenesis, which is critical in the growth and survival of solid tumors. Positive top-line results from a Phase 3 clinical study in advanced renal cell carcinoma (RCC) have been reported, and the drug is also being evaluated in other tumors.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES